

Resignation of Non-Executive Director

SYDNEY, AUSTRALIA – October 5, 2026 – ImmuteP Limited (ASX: IMM; NASDAQ: IMMP) advises that Mr Pete Meyers has resigned as a Non-Executive Director and Deputy Chairman of the Company, effective 2 October 2026. Mr Meyers also served as Chair of the Company’s Audit and Risk Committee.

The Board thanks Mr Meyers for his contribution to ImmuteP during his tenure and wishes him well.

The Board has commenced a process to appoint a new Non-Executive Director and will update the market in due course.

About ImmuteP

ImmuteP is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. ImmuteP is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immuteP.com.

Australian Investors/Media:

Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com

US Investors/Media

Matthew Beck, astr partners
+1 (917) 415-1750; matthew.beck@astrpartners.com

This announcement was authorised for release by the Board of ImmuteP Limited.

